uniQure (QURE) CEO Matthew Kapusta Buys $148K of Stock

CEO Matthew Kapusta Expands Holdings in uniQure N.V.

uniQure N.V. (NasdaqGS: QURE) saw Chief Executive Officer Matthew Kapusta purchase 4,656 shares of company stock on June 18, 2026. The transaction took place at a price of $31.71 per share, resulting in a total investment of $147,641.76. Executive transactions of this nature offer a close look at how leadership manages personal capital in the business.

Inside the Recent Insider Transactions at uniQure

This purchase joins a flurry of reported trading activity by company insiders throughout June. On June 17, 2026, Mr. Kapusta made a larger investment by acquiring 62,581 shares at $19.39 each, totaling about $1.21 million, alongside a purchase of 11,685 shares by Madhavan Balachandran at $24.97 per share. Later in the month on June 24, 2026, the CEO bought another 4,128 shares at $31.71 while also disposing of 6,696 shares under a pre-arranged plan at $50.00 each. Chief Medical Officer Walid Abi-Saab also sold 1,434 shares on June 26, 2026, at an average price of $46.86 for a total of $67,197.24.

Stock Valuation and Market Context

Shares of uniQure trade around $45.77, sitting well above their 52-week low of $8.73 while remaining below the peak of $71.50 reached over the past year. The biotechnology firm commands a market capitalization of roughly $1.56 billion. The stock's 50-day moving average rests at $40.20, while the 200-day moving average stands lower at $29.66.

Wall Street Analyst Outlook and Ratings

Analyst sentiment around the company includes several recent updates from major financial institutions. On June 25, 2026, Mizuho maintained an outperform rating while raising its price target to $68.00 from $35.00. HC Wainwright & Co. followed on June 29, 2026, keeping a buy rating and lifting its target to $80.00 from $50.00. Wells Fargo maintained an overweight rating on July 30, 2026, with a $75.00 target, and Wolfe Research upgraded the stock to an outperform rating that same day with a $65.00 target. Goldman Sachs kept a neutral rating with a $31.00 target on September 30, 2026, followed by RBC Capital maintaining an outperform rating and adjusting its target to $48.00 from $65.00 on October 2, 2026. Barclays rounded out the autumn updates on October 5, 2026, by downgrading the shares to an equal-weight rating with a $28.00 target from $60.00. Across the broader community, the stock holds a consensus strong buy rating and a mean price target of $61.46.

Overview of uniQure Operations

Headquartered in Amsterdam, the Netherlands, uniQure N.V. develops gene therapies aimed at treating rare and devastating medical conditions. Its commercial portfolio features HEMGENIX, a treatment for hemophilia B that helps patients produce factor IX. The firm's clinical pipeline includes AMT-130 for Huntington's disease, AMT-260 for mesial temporal lobe epilepsy, AMT-162 for amyotrophic lateral sclerosis, and AMT-191 for Fabry disease.

What to Watch Next for QURE

Investors will look toward the company's next scheduled earnings report on November 9, 2026, for further financial updates and progress reports on its clinical pipeline. Insider filings will continue to provide visibility into how executives adjust their personal exposure to the firm over time.